Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Pulm Pharmacol Ther. 2012 Dec;25(6):432–437. doi: 10.1016/j.pupt.2012.02.004

Figure 3. Schematic representation of sPLA2-X-mediated CysLT synthesis by eosinophils.

Figure 3

sPLA2-X causes the release of lysophospholipids (LysoPL) and free fatty acids (FFA), including arachidonic acid (AA) from membrane phospholipids species. sPLA2-X causes CysLT synthesis that is dependent upon cPLA2α a and initiates a Ca2+ flux and cPLA2α phosphorylation in eosinophils. We found that the sPLA2-X causes a Ca2+ flux and that sPLA2-X- and LysoPC-induced CysLT synthesis could be inhibited by p38 and JNK inhibitors but not by a MEK 1/2 inhibitor. Free AA released by sPLA2-X may contribute to additional CysLT synthesis based on the observation that the addition of sPLA2-X to eosinophils treated with fMLP leads to additional CysLT synthesis (Adapted from reference 8).